Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RENB 
Renovaro Biosciences Inc (RENB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: RENB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 87.25% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.38M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.53 | 52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 |
52 Weeks Range 0.27 - 2.10 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.41% | Return on Equity (TTM) -53.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 55777031 | Price to Sales(TTM) - |
Enterprise Value 55777031 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.37 | Shares Outstanding 172119008 | Shares Floating 90925076 |
Shares Outstanding 172119008 | Shares Floating 90925076 | ||
Percent Insiders 47.27 | Percent Institutions 12.85 |
Upturn AI SWOT
Renovaro Biosciences Inc
Company Overview
History and Background
Renovaro Biosciences Inc. (formerly known as Sarpe Biosciences, Inc) focuses on the development of cell, gene, and immunotherapy platforms for cancer treatment. The company has evolved through acquisitions and strategic shifts to focus on immunotherapy.
Core Business Areas
- Cell, Gene, and Immunotherapy: Development of therapies targeting cancer. This includes research and clinical trials for immunotherapies, cell therapies, and gene-based treatments.
Leadership and Structure
The leadership team includes individuals with experience in biotechnology, pharmaceutical development, and clinical research. Organizational structure involves research and development, clinical operations, and corporate management functions.
Top Products and Market Share
Key Offerings
- REN001: A cell-mediated immunotherapy product candidate currently under development for the treatment of pancreatic cancer and other solid tumors. Currently in clinical trial phase. Competitors include companies developing similar immunotherapies like Bristol Myers Squibb and Novartis.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth due to advancements in cancer research and the development of novel therapies. The industry is competitive, with numerous companies developing and commercializing immunotherapies.
Positioning
Renovaro Biosciences Inc is positioned as a biotechnology company focused on innovative immunotherapeutic approaches to cancer treatment. Its competitive advantage lies in its proprietary platforms and ongoing clinical trials.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach billions of dollars, and Renovaro is positioning itself within this space with a particular focus on pancreatic cancer. It seeks to capture market share through successful clinical trial outcomes and subsequent commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy platforms
- Experienced leadership team
- Clinical trials underway
- Focus on unmet medical needs (e.g., pancreatic cancer)
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on clinical trial success
- No currently commercialized products
- High R&D expenses
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or collaborations
- Positive clinical trial results
- Advancements in immunotherapy technologies
Threats
- Competition from established immunotherapy companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn affecting R&D funding
Competitors and Market Share
Key Competitors
- BMY
- NVS
- MRNA
- GILD
Competitive Landscape
Renovaro Biosciences Inc faces significant competition from larger, more established biotechnology and pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety of its therapies and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by strategic acquisitions and pipeline development.
Future Projections: Future growth is highly dependent on the successful completion of clinical trials and subsequent commercialization of its product candidates. Analyst estimates are limited and subject to significant uncertainty.
Recent Initiatives: Recent initiatives include advancing its lead product candidate, REN001, through clinical trials and exploring potential partnerships.
Summary
Renovaro Biosciences is a clinical-stage biotechnology company focused on cell, gene and immunotherapy platforms for cancer treatment. Its success hinges on positive clinical trial outcomes, and faces strong competition from major pharmaceutical companies. The company must carefully manage its resources and strategic partnerships. With limited products, the company relies heavily on future performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Data
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Renovaro Biosciences Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2015-02-02 | CEO & Director Mr. David H. Weinstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://renovarogroup.com |
Full time employees 25 | Website https://renovarogroup.com | ||
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company has a strategic collaboration with Nebul to advance the early detection of cancer and other diseases. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.